"Prospective Studies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Descriptor ID |
D011446
|
MeSH Number(s) |
E05.318.760.500.750.625 N05.715.360.775.175.250.630 N06.850.520.450.500.750.650
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prospective Studies".
Below are MeSH descriptors whose meaning is more specific than "Prospective Studies".
This graph shows the total number of publications written about "Prospective Studies" by people in this website by year, and whether "Prospective Studies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 55 | 55 |
1995 | 0 | 74 | 74 |
1996 | 0 | 77 | 77 |
1997 | 0 | 77 | 77 |
1998 | 0 | 87 | 87 |
1999 | 0 | 97 | 97 |
2000 | 0 | 115 | 115 |
2001 | 0 | 80 | 80 |
2002 | 0 | 107 | 107 |
2003 | 0 | 154 | 154 |
2004 | 0 | 163 | 163 |
2005 | 0 | 148 | 148 |
2006 | 0 | 176 | 176 |
2007 | 0 | 175 | 175 |
2008 | 0 | 183 | 183 |
2009 | 0 | 198 | 198 |
2010 | 0 | 221 | 221 |
2011 | 0 | 247 | 247 |
2012 | 0 | 253 | 253 |
2013 | 0 | 319 | 319 |
2014 | 0 | 303 | 303 |
2015 | 0 | 344 | 344 |
2016 | 0 | 342 | 342 |
2017 | 0 | 415 | 415 |
2018 | 0 | 365 | 365 |
2019 | 0 | 419 | 419 |
2020 | 0 | 401 | 401 |
2021 | 0 | 358 | 358 |
2022 | 0 | 337 | 337 |
2023 | 0 | 281 | 281 |
2024 | 0 | 51 | 51 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prospective Studies" by people in Profiles.
-
YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
Improved Symptom Change Enhances Quality of Dying in Patients With Advanced Cancer: An East Asian Cross-Cultural Study. Oncologist. 2024 Apr 04; 29(4):e553-e560.
-
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res. 2024 Apr 01; 30(7):1319-1326.
-
Frequency of vaccine hesitancy among patients with advanced cancer. Palliat Support Care. 2024 Apr; 22(2):289-295.
-
Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes: A Multicohort Study. Diabetes Care. 2024 Apr 01; 47(4):698-706.
-
Prozone masks elevated SARS-CoV-2 antibody level measurements. PLoS One. 2024; 19(3):e0301232.
-
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64.
-
Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study. Clin Infect Dis. 2024 03 20; 78(3):775-784.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Exp Clin Cancer Res. 2024 Mar 15; 43(1):81.